Flamel Technologies S.A. – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 61
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: FC8B6A7E004EN
Leaflet:

Download PDF Leaflet

Flamel Technologies S.A. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Flamel Technologies S.A. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Flamel Technologies S.A. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Flamel Technologies S.A. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Flamel Technologies S.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Flamel Technologies S.A.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Flamel Technologies S.A.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Flamel Technologies S.A. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Flamel Technologies S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Flamel Technologies S.A..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Flamel Technologies S.A. and identify potential opportunities in those areas.
Flamel Technologies S.A. Snapshot
Flamel Technologies S.A. Overview
Key Information
Key Facts
Flamel Technologies S.A. – Research and Development Overview
Key Therapeutic Areas
Flamel Technologies S.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Flamel Technologies S.A. – Pipeline Products Glance
Flamel Technologies S.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Flamel Technologies S.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Flamel Technologies S.A. – Drug Profiles
IFN alpha-2b XL
  Product Description
  Mechanism of Action
  R&D Progress
IL-2 XL
  Product Description
  Mechanism of Action
  R&D Progress
FT-105
  Product Description
  Mechanism of Action
  R&D Progress
hGH XL
  Product Description
  Mechanism of Action
  R&D Progress
Oncology Product
  Product Description
  Mechanism of Action
  R&D Progress
Ophthalmology Product
  Product Description
  Mechanism of Action
  R&D Progress
Undisclosed Cardiovascular Molecule
  Product Description
  Mechanism of Action
  R&D Progress
Undisclosed Hepatology Molecule
  Product Description
  Mechanism of Action
  R&D Progress
Undisclosed Pain Molecules (Trigger Lock)
  Product Description
  Mechanism of Action
  R&D Progress
Blood Clotting Factors
  Product Description
  Mechanism of Action
  R&D Progress
Flamel Technologies S.A. – Pipeline Analysis
Flamel Technologies S.A. – Pipeline Products by Therapeutic Class
Flamel Technologies S.A. Pipeline Products By Target
Flamel Technologies S.A. – Pipeline Products by Route of Administration
Flamel Technologies S.A. – Pipeline Products by Molecule Type
Flamel Technologies S.A. - Dormant Projects
Flamel Technologies S.A. – Company Statement
Flamel Technologies S.A. – Locations And Subsidiaries
Head Office
Flamel Technologies S.A. - Key Manufacturing Facilities
Recent Developments
Dec 18, 2009: Flamel Technologies Initiates Phase 2a Clinical Trial Of IFN-Alpha-2b XL For The treatment Of Chronic Hepatitis C Virus
Apr 25, 2008: Flamel Technologies Presents Results Of Two Week Study Of Interferon Alpha XL At The European Association
Oct 25, 2007: Flamel Technologies Announces Positive Top Line Results Of A Clinical Trial Of IFN-alpha-XL Versus PegIntron In Patients With Chronic Hepatitis C Virus Infection
Oct 18, 2007: Flamel Technologies Announces Positive Results Of A Phase I Trial Of FT-105 Basal Insulin Versus Lantus
Sep 23, 2005: Flamel Technologies Announces Positive Preliminary Results Of A Phase I/II Trial Of IFN-alpha-XL In Patients With Chronic Hepatitis C Virus Infection
Jul 14, 2005: There is a tremendous therapeutic need (and corresponding market opportunity)
Mar 03, 2005: Flamel Technologies Announces Announces Termination of Licensing Agreement For Genvir And Recovery of Rights
Dec 17, 2004: Flamel Technologies Announces Initiation Of Phase I/II Trial Of Medusa Formulation Of Long-Acting Interferon-alpha For Hepatitis B And Hepatitis C Treatment
Dec 17, 2004: Flamel Technologies Announces Initiation Of Phase I/II Trial Of Medusa Formulation Of Long-Acting Interferon-alpha For Hepatitis B And Hepatitis C Treatment
Apr 09, 2003: Biovail Acquires Rights To Controlled Release Acyclovir, Genvir From Flamel Technologies
Financial Deals Landscape
Flamel Technologies S.A., Deals Volume Summary, 2004 to YTD 2010
Flamel Technologies S.A., Deals Summary By Region, 2004 to YTD 2010
Flamel Technologies S.A., Deals Summary, 2004 to YTD 2010
Flamel Technologies S.A. Detailed Deal Summary
Baxter International Enters Into Co-Development Agreement With Flamel Technologies
Licensing Agreements
Flamel Technologies Enters Into Licensing Agreement Pfizer
Flamel Technologies Enters Into Licensing Agreement With Merck Serono
Flamel Technologies Enters Into Licensing Agreement With Merck Serono
Flamel Technologies Enters Into Licensing Agreement With Wyeth Pharmaceuticals
Flamel Technologies Enters Into Licensing Agreement With TAP Pharmaceutical
Flamel Technologies Terminates Licensing Agreement With Bristol-Myers Squibb
Flamel Technologies Terminates Licensing Agreement With Biovail
Flamel Technologies Terminates Licensing Agreement With TAP Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Flamel Technologies S.A. – Pipeline by Therapy Area and Indication, 2010
Flamel Technologies S.A. – Pipeline by Stage of Development, 2010
Flamel Technologies S.A. – Monotherapy Products in Pipeline, 2010
Flamel Technologies S.A. - Phase II, 2010
Flamel Technologies S.A. - Phase I, 2010
Flamel Technologies S.A. - Pipeline By Therapeutic Class, 2010
Flamel Technologies S.A. - Pipeline By Target, 2010
Flamel Technologies S.A. – Pipeline By Route of Administration, 2010
Flamel Technologies S.A. – Pipeline By Molecule Type, 2010
Flamel Technologies S.A. - Dormant Developmental Projects, 2010
Flamel Technologies S.A., Key Manufacturing Facilities
Flamel Technologies S.A., Deals Summary, 2004 to YTD 2010
Flamel Technologies S.A., Deals Summary by Region, 2004 to YTD 2010
Flamel Technologies S.A., Deals Summary, 2004 to YTD 2010 45

LIST OF FIGURES

Flamel Technologies S.A. – Pipeline by Therapy Area and Indication, 2010
Flamel Technologies S.A. – Pipeline by Stage of Development, 2010
Flamel Technologies S.A. – Monotherapy Products in Pipeline, 2010
Flamel Technologies S.A. – Pipeline By Therapeutic Class, 2010
Flamel Technologies S.A. - Pipeline By Target, 2010
Flamel Technologies S.A. – Pipeline By Route of Administration, 2010
Flamel Technologies S.A. – Pipeline By Molecule Type, 2010 30

Ask Your Question

Flamel Technologies S.A. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: